.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advances in Biomarker-Driven Therapy for Advanced NSCLC

Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.

EP. 1: Importance of Biomarker Testing in NSCLC

May 20th 2021

Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.

EP. 2: Targetable Gene Alterations in NSCLC

May 27th 2021

An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.

EP. 3: NSCLC: Targeted Therapy Landscape

June 1st 2021

Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.

EP. 4: The Role of MET in NSCLC

June 1st 2021

A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.

EP. 5: The VISION Trial

June 1st 2021

An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.

EP. 6: Implications of the VISION Trial for Clinical Practice

June 1st 2021

Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.

EP. 7: Looking Ahead in the Treatment of NSCLC

June 1st 2021

Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.